Information Provided By:
Fly News Breaks for November 19, 2019
Nov 19, 2019 | 08:37 EDT
SunTrust analyst Robyn Karnauskas raised her price target on Dicerna (DRNA) to $28 and kept her Buy rating, saying the company's collaboration with Novo Nordisk (NVO) on liver-related cardiometabolic disease candidates demonstrate its ability to participate in larger deals with upside optionality. The analyst believes that Dicerna can become a "larger platform play" over the long term, comparable to Ionis Pharma (IONS) and Alnylam (ALNY).
News For DRNA;NVO;IONS;ALNY From the Last 2 Days
There are no results for your query DRNA;NVO;IONS;ALNY